January 23, 2018 07:39 AM EST

Lining up against rivals, Amgen and Novartis build a blockbuster case for their CGRP migraine drug

Amgen $AMGN and its partners at Novartis $NVS rolled out a fresh batch of solidly positive data from the latest Phase III study of their …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lin­ing up against ri­vals, Am­gen and No­var­tis build a block­buster case for their CGRP mi­graine drug